Study guide
10.2 IP Shipping, Receipt, Temperature Monitoring, Excursion Handling & Chain of Custody
ACRP Certified Professional ACRP-CP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: GCP Principles, Roles & Delegation
1.1 The Eleven ICH E6(R3) Principles of GCP & Guideline Structure 1.2 Sponsor & Investigator Responsibilities and Delegation of Authority 1.3 Staff Training, Qualifications & Delegation of Authority Log (DOAL) 1.4 CRO Oversight, Vendor Management & Transfer of Regulatory Obligations (TORO)
2 Chapter 2: Essential Records, Source Documentation & Data Confidentiality
2.1 Essential Records Before, During and After the Trial (ICH E6(R3) Appendix C) 2.2 Trial Master File (TMF) and Investigator Site File (ISF) Structure & Inspection Readiness 2.3 Source Documentation, ALCOAC Principles & Medical Record Standards 2.4 Confidentiality, Privacy & Protection of Participant Personal Information
3 Chapter 3: Monitoring, Quality Management & Audits
3.1 Risk-Based Quality Management (RBQM) & Quality Management Systems (QMS) 3.2 Monitoring Visit Types: Site Selection, SIV, IMV, and Close-Out 3.3 Risk-Based Monitoring (RBM), Centralized Monitoring & Source Data Verification (SDV vs SDR) 3.4 Quality Audits, Regulatory Inspections, Non-Compliance & Root Cause Analysis / CAPA
4 Chapter 4: Site Feasibility, Start-Up, Facilities & Laboratory Operations
4.1 Site Feasibility Assessment, Capability Analysis & Investigator Selection 4.2 Contractual Agreements: Clinical Trial Agreements, Budgets, Indemnification & Financial Arrangements 4.3 Site Initiation Preparation, System Access & Regulatory Greenlight 4.4 Protocol Review, Operational Feasibility & Institutional Approvals 4.5 Site Facilities, Equipment Maintenance, Calibration & Trial Supplies 4.6 Biological Samples & Hazardous Goods: Collection, Storage, Disposal & Shipment
5 Chapter 5: Subject Recruitment, Retention & Study Visits
5.1 Subject Recruitment Strategies, Advertising Guidelines & Ethical Constraints 5.2 Screening, Eligibility Verification & Inclusion/Exclusion Adherence 5.3 Subject Retention, Compliance, Visit Scheduling & Protocol Window Management 5.4 Managing Lost to Follow-Up, Subject Withdrawal & Early Termination Procedures
6 Chapter 6: Protocol Compliance, Deviations & Site Close-Out
6.1 Protocol Compliance, Waivers vs. Violations & Deviation Management 6.2 Investigational Site Close-Out Activities & Final Reconciliations 6.3 Record Retention, Archiving Requirements & Post-Trial Responsibilities
7 Chapter 7: Research Ethics, Vulnerable Populations & Research Integrity
7.1 Historical Milestones: Nuremberg Code, Belmont Report & Declaration of Helsinki 7.2 Ethical Principles: Beneficence, Non-Maleficence, Autonomy, Justice & Equipoise 7.3 Vulnerable Populations (Pediatrics, Pregnant Women, Prisoners, Cognitively Impaired, Economically Disadvantaged) 7.4 Conflict of Interest, Research Misconduct & Fraud in Clinical Research
8 Chapter 8: Informed Consent & Institutional Review Boards (IRB/IEC)
8.1 Informed Consent Elements, Process & Ongoing Consent / Re-Consent Requirements 8.2 Assent in Minors & Legally Acceptable Representative (LAR) Requirements 8.3 IRB/IEC Composition, Functions, Review Types (Full, Expedited, Exempt) & Continuing Review
9 Chapter 9: Safety Reporting & Adverse Event Management (ICH E2A)
9.1 Adverse Events (AE) vs. Adverse Drug Reactions (ADR) & Serious Adverse Events (SAE) Definitions 9.2 Causality Assessment, Expectedness, Reference Safety Information (RSI) & SUSARs 9.3 Expedited Reporting Timelines (7-day fatal/life-threatening, 15-day other serious) & Periodic Safety Updates (DSUR)
10 Chapter 10: Investigational Product (IP) Management & Accountability
10.1 Investigational Product Lifecycle, Labeling, Packaging & Blinding Procedures 10.2 IP Shipping, Receipt, Temperature Monitoring, Excursion Handling & Chain of Custody 10.3 IP Storage, Dispensing, Accountability Logs & Destruction/Return Procedures 10.4 Emergency Unblinding (Code Breaking) Protocols & Subject Safety Procedures
11 Chapter 11: Regulatory Frameworks, Submissions & Product Reference Information
11.1 Stakeholders, Regulatory Institutions & Global Frameworks in Clinical Research 11.2 Protocol Submission, Approval & Amendment Processes 11.3 Investigator's Brochure, Instructions for Use & Reference Product Information 11.4 Regulatory Reporting Requirements Before and After Marketing Authorisation
12 Chapter 12: Clinical Data Management, EDC & Electronic Records
12.1 Electronic Data Capture (EDC), eCRF Design & Clinical Data Management Systems (CDMS) 12.2 Computerised Systems, Data Governance & Audit Trails (ICH E6(R3) Annex 1 §4) 12.3 Data Validation, Edit Checks, Discrepancy / Query Management & Resolution 12.4 Medical Coding (MedDRA, WHO Drug), SAE Reconciliation, Data Transfer & Database Lock
13 Chapter 13: Trial Design, Biostatistics, Data Monitoring & Transparency
13.1 Phases of Clinical Research (Phase 0, I, II, III, IV) & Translational Medicine 13.2 Study Designs: Parallel, Crossover, Factorial, Adaptive & Non-Inferiority / Equivalence 13.3 Randomization Schemes, Stratification, Blinding Methods & Minimizing Bias 13.4 Endpoints (Primary, Secondary, Surrogate, Composite), Sample Size & Biostatistical Concepts (p-values, CI, ITT vs PP) 13.5 Interim Analyses, DSMB/IDMC Oversight & Efficacy and Safety Evaluation Milestones 13.6 Trial Registration, Results Transparency & Communicating Results to Participants
10.2 IP Shipping, Receipt, Temperature Monitoring, Excursion Handling & Chain of Custody
Key Takeaways Explain This Topic AI
Investigational products must be shipped, handled, and stored across strictly validated temperature tiers: Controlled Room Temperature / Ambient (15°C to 25°C), Refrigerated (2°C to 8°C), Frozen (-20°C ± 5°C), Ultra-Low (-80°C ± 10°C), and Cryogenic (≤ -150°C).
Calibrated, NIST-traceable continuous temperature data loggers must accompany shipments and monitor site storage units; sensors should be immersed in a glycol thermal buffer to reflect actual liquid product temperatures rather than transient air fluctuations.
Upon receipt of an IP shipment, site personnel must immediately inspect the external carton, verify intact tamper seals, download and review the temperature data logger, and reconcile kit/lot numbers against the shipping manifest before acknowledging receipt in the IRT system.
A Temperature Excursion is any out-of-specification temperature event; the mandatory first action is the immediate physical and electronic QUARANTINE of affected IP, marking the inventory 'DO NOT DISPENSE'.
Quarantined investigational products cannot be released for subject dispensing or destroyed until the sponsor's Quality Assurance and stability teams complete a formal technical evaluation and issue written authorization.
Last updated: August 2026
IP Shipping, Receipt, Temperature Monitoring, Excursion Handling & Chain of Custody
Core Regulatory Standard: Investigational Products are sensitive chemical, biological, or gene-based therapeutics whose molecular integrity, pharmacological activity, and safety profile depend entirely on maintaining strict environmental conditions throughout distribution and on-site storage. Under ICH E6(R3) Annex 1 section 2.10 and 21 CFR 312.62 , the Principal Investigator is responsible for ensuring that IP is delivered, stored, and maintained under protocol-specified conditions, that continuous temperature records are preserved, and that any temperature excursion triggers an immediate quarantine protocol to prevent compromised product from reaching research participants.
1. Temperature Storage Classifications & Cold Chain Principles
Clinical trial materials are classified into standardized temperature storage tiers defined by international pharmacopeias (USP, Ph. Eur.) and clinical trial protocols. ┌───────────────────────────────────────────────────────────────────────────┐
- │ CLINICAL TRIAL TEMPERATURE TIERS │
- ├──────────────────────────┬────────────────────────────────────────────────┤
- │ STORAGE CLASSIFICATION │ TEMPERATURE RANGE SPECIFICATION │
- ├──────────────────────────┼────────────────────────────────────────────────┤
- │ Controlled Room Temp │ 15°C to 25°C (59°F to 77°F) │
- │ (CRT / Ambient) │ [Excursions permitted between 15°C and 30°C] │
- ├──────────────────────────┼────────────────────────────────────────────────┤
- │ Refrigerated │ 2°C to 8°C (36°F to 46°F) │
- │ │ [Strict: Freezing (<2°C) causes denaturation] │
- ├──────────────────────────┼────────────────────────────────────────────────┤
- │ Standard Frozen │ -20°C ± 5°C (-15°C to -25°C / 5°F to -13°F) │
- ├──────────────────────────┼────────────────────────────────────────────────┤
- │ Ultra-Low Frozen (ULT) │ -80°C ± 10°C (-70°C to -90°C / -94°F to -130°F)│
- ├──────────────────────────┼────────────────────────────────────────────────┤
- │ Cryogenic (Liquid N2) │ ≤ -150°C (Liquid Nitrogen vapor phase) │
- └──────────────────────────┴────────────────────────────────────────────────┘
- Specialized Cold Chain Shipping Technologies
To maintain temperature integrity during international and domestic transit, sponsors employ validated thermal packaging systems:
Phase-Change Materials (PCMs): Advanced paraffin or salt-hydrate thermal packs engineered to absorb or release latent heat at specific transition temperatures (e.g., maintaining 2°C to 8°C without risk of freezing).
Dry Ice (Solid Carbon Dioxide): Sublimates at -78.5°C; utilized for frozen (-20°C) and ultra-low (-80°C) shipments. Containers require specialized ventilation to prevent pressure buildup.
Liquid Nitrogen Dry Shippers: Insulated vacuum vessels with hydrophobic absorbent layers that hold liquid nitrogen in a vapor state at temperatures below -150°C, essential for cellular and gene therapies.
2. Calibrated Temperature Monitoring & Data Loggers
Continuous temperature verification is mandatory from the manufacturing depot to final patient administration. ┌───────────────────────────────────────────────────────────────────────────┐
- │ CALIBRATION & MONITORING BEST PRACTICES │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 1. NIST TRACEABILITY: All temperature data loggers and storage unit │
- │ thermometers must possess current, documented NIST-traceable │
- │ calibration certificates (re-calibrated annually). │
- │ 2. GLYCOL THERMAL BUFFERS: Temperature probes inside refrigerators and │
- │ freezers must be immersed in a glycol bottle (e.g., 100 mL bottle │
- │ of mineral oil or USP-grade glycol) to measure actual liquid product │
- │ temperature rather than transient air spikes from door openings. │
- │ 3. PROBE POSITIONING: Sensors must be placed in the geometric center of │
- │ the unit, away from cooling fans, interior light bulbs, and doors. │
- │ 4. 24/7 AUTOMATED ALARMS: Storage facilities must utilize continuous │
- │ electronic monitoring with local audible/visual alarms and automated │
- │ 24/7 remote telephone/SMS dialer notifications to on-call staff. │
- └───────────────────────────────────────────────────────────────────────────┘
- Single-Use vs. Continuous Digital Data Loggers
In-Transit Shipment Loggers: Compact electronic data loggers (e.g., Sensitech TempTale, Elpro LIBERO) embedded inside shipping cartons. Upon arrival, the device displays whether the shipment remained within range (green check / OK) or breached a threshold (red alarm / Excursion). The device is stopped, connected via USB to a computer, and the encrypted PDF data file is extracted.
Site Storage Data Loggers: Continuous monitoring devices that log temperature readings at 5- to 15-minute intervals 24 hours a day, 365 days a year. Minimum, maximum, and current temperatures must be reviewed and documented daily by site research personnel.
3. IP Shipment Receipt & Chain of Custody Documentation
When a courier delivers an investigational product shipment to a clinical site, a rigorous, sequential receipt verification procedure must be executed immediately. ┌───────────────────────────────────────────────────────────────────────────┐
- │ STEP-BY-STEP IP RECEIPT WORKFLOW │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ STEP 1: INSPECT EXTERNAL CARTON │
- │ • Check for physical damage, punctures, water leaks, crushed corners │
- │ • Verify airway bill tracking number against shipment notification │
- │ │
- │ STEP 2: CHECK IN-TRANSIT TEMPERATURE LOGGER │
- │ • Retrieve data logger from inside insulated shipping container │
- │ • Check display status (OK / ALARM) │
- │ • Connect to PC, stop recording, and generate encrypted PDF data file │
- │ │
- │ STEP 3: PHYSICAL INVENTORY RECONCILIATION │
- │ • Open inner packaging and verify intact tamper-evident seals │
- │ • Reconcile physical kit numbers, lot numbers, and quantities against │
- │ the sponsor's shipping manifest / packing slip │
- │ │
- │ STEP 4: IMMEDIATE TRANSFER TO VALIDATED STORAGE │
- │ • Place IP into locked, temperature-monitored storage unit immediately │
- │ (Do not leave IP sitting on pharmacy counter or coordinator desk) │
- │ │
- │ STEP 5: IRT / RTSM SYSTEM ACKNOWLEDGMENT & DOCUMENTATION │
- │ • Log into IRT/IWRS web portal and confirm receipt of specific kit IDs │
- │ • Complete, sign, and date the paper Shipping Receipt Confirmation Form │
- │ • File packing slip, courier waybill, and logger report in ISF │
- └───────────────────────────────────────────────────────────────────────────┘
- Chain of Custody Verification
The Chain of Custody establishes an unbroken, legally defensible audit trail tracing every physical movement and transfer of ownership of the investigational product from the manufacturer to the depot, the commercial courier, the site investigator, the research pharmacist, and finally the research subject.
4. Temperature Excursion Management & The Quarantine Protocol
A Temperature Excursion is defined as any variance or deviation from the protocol-specified storage temperature range for any length of time (e.g., an investigational vaccine requiring 2°C to 8°C storage that experiences a temperature rise to 12.5°C due to a facility power interruption). ┌───────────────────────────────────────────────────────────────────────────┐
- │ THE 5-STEP SITE EXCURSION WORKFLOW │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 1. IMMEDIATE QUARANTINE │
- │ • Physically segregate affected IP or affix prominent signage: │
- │ "QUARANTINED - DO NOT DISPENSE" │
- │ • Move to a functional unit maintaining the required temperature │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 2. ELECTRONIC QUARANTINE IN IRT / RTSM │
- │ • Flag all affected kit/bottle numbers as 'QUARANTINED' in the IRT │
- │ • Prevents automated random assignment to active trial subjects │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 3. DOWNLOAD RAW TEMPERATURE DATA & COMPLETE NOTIFICATION FORM │
- │ • Extract continuous data log (.pdf / .csv) showing exact start time, │
- │ peak/trough temperature reached, and duration of the excursion │
- │ • Complete Sponsor Temperature Excursion Assessment Form │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 4. NOTIFY SPONSOR / CRO & UNBLINDED MONITOR IMMEDIATELY │
- │ • Transmit excursion report and raw data file to sponsor/unblinded CRA│
- │ • Request replacement kits if upcoming subject visits are scheduled │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 5. AWAIT FORMAL WRITTEN SPONSOR DISPOSITION │
- │ • UNDER NO CIRCUMSTANCES DISPENSE IP WITHOUT WRITTEN SPONSOR APPROVAL │
- │ • Sponsor QA evaluates stability data -> Issues Release OR Reject │
- └───────────────────────────────────────────────────────────────────────────┘
- Stability Data Evaluation & Sponsor Decision Matrix
When a site reports an excursion, the sponsor's Quality Assurance (QA) and CMC (Chemistry, Manufacturing, and Controls) technical teams perform an analytical stability assessment based on:
Cumulative Thermal Exposure: Total lifetime exposure of that specific manufacturing batch to out-of-range temperatures.
Arrhenius Kinetics & Degradation Pathways: Mathematical modeling of chemical degradation, protein unfolding, or aggregation at elevated temperatures.
Freeze-Thaw Cycling Data: Whether biological macromolecules (e.g., monoclonal antibodies) have undergone fatal physical crystallization.
Mean Kinetic Temperature (MKT): The single calculated isothermal temperature that corresponds to the kinetic effects of a temperature distribution over time.
Potential Sponsor Dispositions:
Released for Clinical Use: Stability data proves the drug maintains 100% potency and safety. The sponsor issues a formal Certificate of Release / Concession Letter , allowing the site to remove the quarantine tag and return kits to active inventory.
Rejected / Destroyed: Stability data indicates potential degradation or lack of supporting stability data. The sponsor updates the IRT status to 'Damaged / Defective' and instructs the site to return kits to the depot or execute on-site destruction.
5. Documenting Excursion Resolution & Inspection Readiness
Every temperature excursion creates an essential compliance trail that regulatory inspectors (FDA BIMO, EMA) inspect during GCP audits. The site must maintain a complete Temperature Excursion Dossier in the Investigator Site File (ISF) containing:
Initial Temperature Logger graph and tabular raw data download.
Completed Site Excursion Notification Form with exact timestamps.
Email correspondence with the Sponsor, CRO, and Unblinded Monitor.
Sponsor Quality Assurance Technical Assessment and Formal Written Disposition Letter.
IRT system audit trail confirming when kits were quarantined and when their status was updated.
Corrective and Preventive Action (CAPA) plan addressing root cause (e.g., emergency generator servicing, replacement of degraded refrigerator door gasket).
6. Realistic Clinical Scenario & ACRP-CP Case Analysis
Clinical Scenario: On Monday morning at 07:30, Clinical Research Coordinator Elena Rossi arrives at the research clinic after a severe weekend summer storm. Upon checking the digital thermometer on the investigational refrigerator (specified range: 2.0°C to 8.0°C), she observes a current reading of 14.8°C.
Elena checks the continuous NIST-traceable data logger and discovers that power was lost on Saturday at 22:00. The refrigerator temperature exceeded 8.0°C on Sunday at 02:00, reached a peak of 15.2°C on Sunday afternoon, and remained above 8.0°C for a total duration of 29.5 consecutive hours. Inside the refrigerator are 12 kits of an investigational biologic for an active Phase III oncology trial, and Subject #003 is scheduled to receive an infusion at 10:00 that morning.
ACRP-CP Step-by-Step Action Plan & Critical Decision Analysis:
Immediate Quarantine (Stop Dosing): Elena must immediately mark all 12 kits with bright yellow "QUARANTINED - DO NOT DISPENSE" labels and transfer them to a functional, backup 2°C to 8°C monitored unit. Under no circumstances may Subject #003 be infused with medication from this refrigerator at 10:00.
Electronic Quarantine: Elena logs into the IRT/RTSM system and changes the status of all 12 kit IDs from 'Available' to 'Quarantined - Excursion' , preventing accidental dispensing.
Subject Management: Elena contacts the PI (Dr. Adams) and the subject. If alternative validated kits are not available on site, Subject #003's infusion must be safely rescheduled within the protocol-allowed visit window, or urgent replacement kits requested from the central depot.
Data Download & Sponsor Reporting: Elena stops the logger, downloads the complete PDF/CSV temperature profile, and submits the Sponsor Excursion Report to the Sponsor Medical Monitor and Unblinded CRA by 08:30.
Resolution: Two days later, the sponsor's QA stability team confirms that the biologic denatures irreversibly when exposed to temperatures >10.0°C for >12 hours. The sponsor issues a written directive declaring all 12 kits 'Unusable - Return to Depot' . New replacement kits arrive via priority courier the following morning. Elena files all correspondence, logger files, return airbills, and the sponsor rejection letter in the Pharmacy Binder.